KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Non-Current Assets (2016 - 2025)

TherapeuticsMD's Other Non-Current Assets history spans 16 years, with the latest figure at $444000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 241.54% year-over-year to $444000.0; the TTM value through Dec 2025 reached $444000.0, up 241.54%, while the annual FY2025 figure was $444000.0, 241.54% up from the prior year.
  • Other Non-Current Assets reached $444000.0 in Q4 2025 per TXMD's latest filing, down from $470000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $470000.0 in Q3 2025 to a low of $58000.0 in Q4 2023.
  • Average Other Non-Current Assets over 5 years is $236850.0, with a median of $253000.0 recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: tumbled 99.54% in 2021, then soared 710.34% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $253000.0 in 2021, then changed by 0.0% to $253000.0 in 2022, then plummeted by 77.08% to $58000.0 in 2023, then soared by 124.14% to $130000.0 in 2024, then surged by 241.54% to $444000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Other Non-Current Assets are $444000.0 (Q4 2025), $470000.0 (Q3 2025), and $428000.0 (Q2 2025).